{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:33:04Z","timestamp":1769819584716,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of stent placement combined with intraluminal radiofrequency ablation (intra-RFA) and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced biliary tract cancers (Ad-BTCs) and biliary obstruction (BO).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed data for patients with Ad-BTCs and BO who underwent stent placement with or without intra-RFA and HAIC in three centres between November 2013 and November 2018. The stent patency time (SPT), overall survival (OS), and adverse events (AEs) were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 135 enrolled patients, 64 underwent stent placement combined with intra-RFA and HAIC, while 71 underwent only stent placement. The median SPT was significantly longer in the combination group (8.2 months, 95% confidence interval [CI]: 7.1\u20139.3) than in the control group (4.3 months, 95% CI: 3.6\u20135.0; <jats:italic>p<\/jats:italic> &lt; 0.001). A similar result was observed for OS (combination: 13.2 months, 95% CI: 11.1\u201316.5; control: 8.5 months, 95% CI: 7.6\u20139.6; <jats:italic>p<\/jats:italic> &lt; 0.001). The incidence of AEs related to biliary tract operation was not significantly different between the two groups (<jats:italic>p<\/jats:italic> &gt; 0.05). The most common AE and serious AE related to HAIC were alanine aminotransferase elevation (24\/64; 37.5%) and thrombocytopenia (8\/64; 12.5%), respectively. All AEs were tolerable, and there was no death from AEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Stent placement combined with intra-RFA and HAIC may be a safe, potential treatment strategy for patients with Ad-BTCs and BO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:italic>\u2022 Advanced biliary cancers (Ad-BTCs) with biliary obstruction (BO) can rapidly result in liver failure and cachexia with an extremely poor prognosis.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 Stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy may be safe and effective for patients with Ad-BTCs and BO.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 The long-term efficacy and safety of the combined treatment is promising.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-021-07716-0","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:13:40Z","timestamp":1613607220000},"page":"5851-5862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy for advanced biliary tract cancers with biliary obstruction: a multicentre, retrospective, controlled study"],"prefix":"10.1007","volume":"31","author":[{"given":"Qing","family":"Gou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qicong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongde","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weike","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qichun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8315-4280","authenticated-orcid":false,"given":"Zejian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"7716_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168\u20132179","journal-title":"Lancet"},{"key":"7716_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261\u2013280","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7716_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","volume":"37","author":"SA Khan","year":"2002","unstructured":"Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806\u2013813","journal-title":"J Hepatol"},{"key":"7716_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/gut.48.6.816","volume":"48","author":"SD Taylor-Robinson","year":"2001","unstructured":"Taylor-Robinson SD, Toledano MB, Arora S et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968\u20131998. Gut 48:816","journal-title":"Gut"},{"key":"7716_CR5","first-page":"487","volume":"86","author":"R F","year":"2015","unstructured":"F R, Settmacher U (2015) Liver resection for intrahepatic cholangiocarcinoma. Der Chirurg Zeitschrift F\u00fcr Alle Gebiete Der Operativen Medizen 86:487\u2013492","journal-title":"Der Chirurg Zeitschrift F\u00fcr Alle Gebiete Der Operativen Medizen"},{"issue":"Suppl 7","key":"7716_CR6","doi-asserted-by":"publisher","first-page":"vii345","DOI":"10.1093\/annonc\/mdq420","volume":"21","author":"JW Valle","year":"2010","unstructured":"Valle JW (2010) Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol 21(Suppl 7):vii345\u2013vii348","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"7716_CR7","first-page":"iv103","volume":"30","author":"S Berrad","year":"2019","unstructured":"Berrad S, Oualla K, Nouikh L et al (2019) Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers. Ann Oncol 30(Suppl 4):iv103","journal-title":"Ann Oncol"},{"key":"7716_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/liv.12325","volume":"34","author":"M Pinter","year":"2014","unstructured":"Pinter M, Hucke F, Zielonke N et al (2014) Incidence and mortality trends for biliary tract cancers in Austria. Liver Int 34:1102\u20131108","journal-title":"Liver Int"},{"key":"7716_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ajg.2016.512","volume":"112","author":"MA Almadi","year":"2017","unstructured":"Almadi MA, Barkun A, Martel M (2017) Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol 112:260\u2013273","journal-title":"Am J Gastroenterol"},{"key":"7716_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.gie.2015.10.035","volume":"83","author":"MA Almadi","year":"2016","unstructured":"Almadi MA, Barkun A, Martel M (2016) Self-expandable metal stents versus plastic stents for malignant biliary obstruction. Gastrointest Endosc 83:852\u2013853","journal-title":"Gastrointest Endosc"},{"key":"7716_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.gie.2018.03.029","volume":"88","author":"M Conio","year":"2018","unstructured":"Conio M, Mangiavillano B, Caruso A et al (2018) Covered versus uncovered self-expandable metal stent for palliation of primary malignant extrahepatic biliary strictures: a randomized multicenter study. Gastrointest Endosc 88:283\u2013291.e283","journal-title":"Gastrointest Endosc"},{"key":"7716_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jhep.2018.12.027","volume":"70","author":"A Doyle","year":"2019","unstructured":"Doyle A, Gorgen A, Muaddi H et al (2019) Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 70:866\u2013873","journal-title":"J Hepatol"},{"key":"7716_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/17474124.2017.1314784","volume":"11","author":"AK Dutta","year":"2017","unstructured":"Dutta AK, Basavaraju U, Sales L, Leeds JS (2017) Radiofrequency ablation for management of malignant biliary obstruction: a single-center experience and review of the literature. Expert Rev Gastroenterol Hepatol 11:779\u2013784","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"7716_CR14","doi-asserted-by":"publisher","unstructured":"Inoue T, Ibusuki M, Kitano R et al (2020) Endobiliary radiofrequency ablation combined with bilateral metal stent placement for malignant hilar biliary obstruction. Endoscopy. https:\/\/doi.org\/10.1055\/a-1133-4448","DOI":"10.1055\/a-1133-4448"},{"key":"7716_CR15","first-page":"853","volume":"33","author":"W Cui","year":"2017","unstructured":"Cui W, Wang Y, Fan W et al (2017) Comparison of intraluminal radiofrequency ablation and stents vs. stents alone in the management of malignant biliary obstruction. Int J Hyperthermia 33:853\u2013861","journal-title":"Int J Hyperthermia"},{"key":"7716_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.gie.2017.10.029","volume":"87","author":"AA Sofi","year":"2018","unstructured":"Sofi AA, Khan MA, Das A et al (2018) Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 87:944\u2013951 e941","journal-title":"Gastrointest Endosc"},{"key":"7716_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/annonc\/mdm528","volume":"19","author":"A Ganeshan","year":"2008","unstructured":"Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R (2008) Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 19:847\u2013851","journal-title":"Ann Oncol"},{"key":"7716_CR18","doi-asserted-by":"publisher","unstructured":"Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007823.pub2:Cd007823","DOI":"10.1002\/14651858.CD007823.pub2:Cd007823"},{"key":"7716_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R et al (2019) Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol 5:953\u2013960","journal-title":"JAMA Oncol"},{"key":"7716_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu N, Kong Y, Mu L et al (2018) Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 69:60\u201369","journal-title":"J Hepatol"},{"key":"7716_CR21","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1245\/s10434-014-3766-7","volume":"21","author":"K Kasai","year":"2014","unstructured":"Kasai K, Kooka Y, Suzuki Y et al (2014) Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon \u03b1-2b for advanced intrahepatic cholangiocarcinoma. Ann Surg Oncol 21:3638\u20133645","journal-title":"Ann Surg Oncol"},{"key":"7716_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2019","unstructured":"Cercek A, Boerner T, Tan BR et al (2019) Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6:60\u201367","journal-title":"JAMA Oncol"},{"key":"7716_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1148\/radiol.2016160572","volume":"283","author":"X Wang","year":"2017","unstructured":"Wang X, Hu J, Cao G et al (2017) Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology 283:580\u2013589","journal-title":"Radiology"},{"key":"7716_CR24","doi-asserted-by":"publisher","unstructured":"Liao X, Zhang D (2020) The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary cancer: a review and update. Arch Pathol Lab Med. https:\/\/doi.org\/10.5858\/arpa.2020-0032-RA","DOI":"10.5858\/arpa.2020-0032-RA"},{"key":"7716_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.gie.2010.10.018","volume":"74","author":"A Monga","year":"2011","unstructured":"Monga A, Gupta R, Ramchandani M, Rao GV, Santosh D, Reddy DN (2011) Endoscopic radiofrequency ablation of cholangiocarcinoma: new palliative treatment modality (with videos). Gastrointest Endosc 74:935\u2013937","journal-title":"Gastrointest Endosc"},{"key":"7716_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7150\/jca.23280","volume":"9","author":"M Mizandari","year":"2018","unstructured":"Mizandari M, Kumar J, Pai M et al (2018) Interventional radiofrequency ablation: a promising therapeutic modality in the management of malignant biliary and pancreatic duct obstruction. J Cancer 9:629\u2013637","journal-title":"J Cancer"},{"key":"7716_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/s-0043-124870","volume":"50","author":"J Yang","year":"2018","unstructured":"Yang J, Wang J, Zhou H et al (2018) Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 50:751\u2013760","journal-title":"Endoscopy"},{"key":"7716_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1499-3872(13)60066-1","volume":"12","author":"H Alis","year":"2013","unstructured":"Alis H, Sengoz C, Gonenc M, Kalayci MU, Kocatas A (2013) Endobiliary radiofrequency ablation for malignant biliary obstruction. Hepatobiliary Pancreat Dis Int 12:423\u2013427","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"7716_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno PM, Liu Y, Park GY et al (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461\u2013471","journal-title":"Nat Med"},{"key":"7716_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/01.cad.0000198912.98442.cd","volume":"17","author":"B Qin","year":"2006","unstructured":"Qin B, Tanaka R, Shibata Y et al (2006) In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs 17:445\u2013453","journal-title":"Anticancer Drugs"},{"key":"7716_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","volume":"15","author":"R Dzodic","year":"2004","unstructured":"Dzodic R, Gomez-Abuin G, Rougier P et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 15:647\u2013650","journal-title":"Anticancer Drugs"},{"key":"7716_CR32","doi-asserted-by":"crossref","unstructured":"Furuta M, Watanabe J, Aramaki T (2018) 318PClinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: a review of a single institution. Ann Oncol 29","DOI":"10.1093\/annonc\/mdy272.308"},{"key":"7716_CR33","doi-asserted-by":"publisher","unstructured":"Palmieri LJ, Dermine S, Coriat R (2019) Potential areas of interest in a trial of sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for hepatocellular carcinoma. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4052","DOI":"10.1001\/jamaoncol.2019.4052"},{"key":"7716_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1056\/NEJMc1005317","volume":"363","author":"FM Hall","year":"2010","unstructured":"Hall FM (2010) Cisplatin plus gemcitabine for biliary tract cancer. N Engl J Med 363:192 author reply 192-193","journal-title":"N Engl J Med"},{"key":"7716_CR35","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950\u20131958","journal-title":"Ann Oncol"},{"key":"7716_CR36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Groot Koerkamp B, Do RK et al (2016) Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 122:758\u2013765","journal-title":"Cancer"},{"key":"7716_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12885-017-3278-5","volume":"17","author":"W Cui","year":"2017","unstructured":"Cui W, Fan W, Lu M et al (2017) The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: a single-institution experience. BMC Cancer 17:288","journal-title":"BMC Cancer"},{"key":"7716_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10555-018-09777-y","volume":"38","author":"O Thews","year":"2019","unstructured":"Thews O, Riemann A (2019) Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev 38:113\u2013129","journal-title":"Cancer Metastasis Rev"},{"key":"7716_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.radonc.2020.03.017","volume":"147","author":"W Zhou","year":"2020","unstructured":"Zhou W, Qian L, Rong Y et al (2020) Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol 147:111\u2013117","journal-title":"Radiother Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-07716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-07716-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-07716-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T11:34:05Z","timestamp":1625830445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-07716-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["7716"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-07716-0","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,13]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Zejian Zhou.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Institutional Review Board of Provincial People\u2019s Hospital\/ Guangdong Academy of Medical Sciences, China.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 Retrospective\u2022 Diagnostic or prognostic study\u2022 Multicenter study","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}